Diagnósticos da América (DASA3) Q3 2025 earnings summary

Executive summary

• Achieved national leadership in diagnostic medicine, with strong revenue growth in premium, home care, and B2B segments, supported by divestments totaling R$704.8 million and a strengthened management team.

• Enhanced productivity and efficiency through process standardization, digitalization, and organizational optimization, launching 80 new products/services in 2024.

• Focused on core business, with strategic divestments in Argentina, Mantris, and innovation/occupational medicine businesses to reinforce capital structure and simplify operations.

• Rede Américas joint venture delivered consistent improvement in key performance indicators, with gross revenue of R$3.4 billion and EBITDA margin at 19.6%.

• Productivity, digitalization, and B2B now represent over half of all diagnostic exams.

Financial highlights

• Consolidated gross revenue reached R$2.9 billion in 3Q25, with Diagnostics up 12% and Hospitals/Oncology NE up 7% year-over-year.

• Gross margin improved by 5 percentage points to 33.8%, and EBITDA margin expanded by 7.6 p.p. to 26.5% compared to Q3 2024.

• Operating cash generation was R$481 million, up over 113% year-over-year, and free cash flow rose to R$415 million, up 251%.

• Net income was R$97 million, reversing a R$87 million loss in 3Q24.

• Net financial debt reduced to R$6.6 billion, with leverage at 2.38x EBITDA, down from 4.17x a year ago.

Outlook and guidance

• Management remains focused on further margin expansion, operational efficiency, and disciplined capital allocation, with ongoing digitalization and process optimization.

• Selective expansion and prioritization of high-return investment projects continue.

• Positive outlook for premium and B2B segments, with market share gains anticipated.